Indian Generics Face $300 Million In Annual U.S. User Fees Under Bill
This article was originally published in PharmAsia News
Executive Summary
Indian generics makers collectively would have to pay an estimated $300 million a year to get their drug versions approved by U.S. FDA, according to pending legislation.